



April 1, 2010

RE: IMPORTANT SUPPLY INFORMATION

Extended backorder for MUSTARGEN® (mechlorethamine HCL for injection), 10 mg/vial
(NDC No. 67386-911-51)

Dear Healthcare Professional,

Lundbeck Inc. (Lundbeck), a wholly owned subsidiary of H. Lundbeck A/S, has worked diligently for several years to transfer the manufacturing of Mustargen® to a new manufacturing site. This has been a challenging process since more than 20 contractors declined to manufacture our sterile, dry powder, cytotoxic injectable drug product. Therefore, Lundbeck invested more than \$3 million to build a new and dedicated manufacturing suite for the product at the new contractor.

After construction was completed and documentation for approval was filed in the US in December 2009, we recently learned that our contractor will no longer pursue commercial manufacturing.

As a result, we now expect an extended supply shortage. We are doing everything we can to minimize this disruption in supply, including the investment in an expedited transfer program to a second manufacturing site. We have great confidence in the ability of our new manufacturer to produce a high quality product, however, approval is not expected before 2011.

Our remaining supply of product (which will not become available until the end of April 2010) is very limited in terms of quantity and dating. To enable as many patients as possible to have an orderly transition to alternative therapies, FDA requested that we develop a fair allocation plan and continue to drop-ship product until our inventory is exhausted. Patients who are currently being administered Mustargen in a course of therapy will be given priority in our allocation of this product. Due to the limited supply physicians are encouraged to consider alternative therapy rather than starting a new course of therapy with Mustargen.

We regret this extended supply gap and are committed to securing a new long-term source for patients. While we focus on resuming production as quickly as possible, customers should contact their local healthcare provider or oncology organizations to discuss interim solutions as there may be alternatives available for some indications. Customers may also wish to consult the following websites:

- www.fda.gov/drugs/drugsafety/drugshortages/default.htm
- <http://www.ashp.org/shortages>

Sincerely,

Mark Weinberg, Vice President, US Medical Affairs

Mustargen® is a registered trademark of Lundbeck Inc.